Adipotide (also called FTPP or Prohibitin-TP01) is an experimental peptidomimetic designed to target the blood supply of white fat tissue. It is a research compound, not an approved medicine.

What does research suggest about Adipotide?

In animal studies, including obese non-human primates, Adipotide produced weight and fat-mass loss. However, the same studies also reported kidney toxicity, and there is no established human clinical evidence of safety or benefit.

Is Adipotide approved or safe for human use?

No. Adipotide is not an approved medicine in any jurisdiction and has never been shown to be safe in humans. It is considered experimental with significant safety concerns and is not intended for human use.

What are the known side effects of Adipotide?

The most significant documented concern is renal (kidney) toxicity observed in primate studies. Dehydration has also been noted. Its full safety profile in humans is unknown because human data does not exist.

How does Adipotide work?

Adipotide was engineered to target the vasculature of white adipose tissue, aiming to reduce the blood supply that sustains fat stores. This mechanism differs from appetite- or metabolism-based approaches and is described only from preclinical research.

What is the legal and regulatory status of Adipotide?

Adipotide is not approved as a medicine and holds an experimental research status. Commercial availability is restricted, and it is not a validated or legal therapeutic product for human use.

How is Adipotide's mechanism different from GLP-1 fat-loss drugs like semaglutide?

They work in completely different ways. GLP-1 receptor agonists act on appetite and metabolic signaling to reduce food intake and body weight, and are approved medicines with large trial programs. Adipotide instead tries to destroy the blood vessels that supply fat tissue, an anti-angiogenic/proapoptotic approach that was never approved and is associated with kidney toxicity in studies. Comparing the two is educational only, not a suggestion to use either without medical oversight.

Why does Adipotide still get talked about if it was never approved?

Much of the attention traces back to a single dramatic primate study in which obese monkeys lost weight. That striking imagery spread widely and gave the compound a reputation as a 'targeted' fat-loss agent. What often gets left out of that retelling is the accompanying kidney toxicity and the absence of successful human trials, which is why its popularity outpaces its actual evidence base.

Is Adipotide a 'natural' hormone or peptide the body makes?

No. This is a common misconception. It is a synthetic, engineered peptidomimetic built from a fat-vasculature homing sequence linked to a cell-killing sequence. It is not a naturally occurring hormone, and its design goal was to selectively damage adipose blood supply rather than to mimic a normal signaling molecule.

Where can I buy Adipotide and compare vendors?

Use the vendor comparison on this page. It shows only checked, product-specific links and identifies vendor claims, independent documentation and affiliate relationships separately. Availability and legal status can vary by country.

Metabolic

Buy Adipotide – Vendors, Prices, Testing and Evidence

Buy Adipotide

Also known as: FTPP · Prohibitin-TP01

Evidence grade D — AnecdotalRisk flag

Short answer

An experimental fat-loss peptide with serious safety concerns (renal toxicity in studies). Not for human use.

Where can you buy Adipotide?

No peptide-specific vendor offer is currently verified. The vendor catalogue link is provided for discovery only and does not assert availability.

What is known?

Adipotide is a peptidomimetic targeting the blood supply of fat tissue.

What is not established?

None established; primate studies showed renal toxicity.

Safety

Documented kidney toxicity in primate studies. Considered unsafe for human use.

Regulatory status

Not an approved medicine. Experimental; significant safety concerns.

Not medical advice. This educational reference is not diagnosis, treatment, prescribing, dosing or emergency guidance. Consult a qualified professional before making health-related decisions.

Regulatory or safety concern: This substance may be unapproved for human use, affect the hormonal system, or be subject to regulator or anti-doping restrictions. Check the cited evidence and rules in your jurisdiction.

Vendor comparison

Buy Adipotide: compare vendors

The table lists only product-specific offers that were checked and for which a real destination exists. Missing prices, quantities, stock and laboratory details are not inferred.

What is it?

Adipotide is a peptidomimetic targeting the blood supply of fat tissue.

Research and evidence

Adipotide, also known as FTPP or Prohibitin-TP01, is an experimental peptidomimetic that was designed to target the blood vessels supplying white adipose (fat) tissue. Rather than acting on appetite or metabolism the way most weight-related compounds do, Adipotide was engineered to bind a receptor associated with the vasculature that feeds fat stores and to trigger the collapse of that blood supply, effectively starving fat tissue. This unusual, vascular-targeting mechanism is the main reason the compound drew scientific and popular attention as a potential obesity research tool. It is important to state plainly at the outset: Adipotide is not an approved medicine anywhere, it has never been established as safe or effective in humans, and it is categorized as experimental with significant safety concerns.

The evidence base for Adipotide is entirely preclinical. In animal studies, including work in obese non-human primates, the compound produced measurable weight and fat-mass loss, which is what generated interest in it as a candidate for further investigation. However, those same primate studies also documented renal (kidney) toxicity, a serious adverse effect that has been central to how the compound is now viewed. There is no established human clinical evidence demonstrating that Adipotide is safe or that any weight-loss benefit would outweigh its risks in people. In other words, the animal signal for fat loss is real in the research record, but it is inseparable from a documented toxicity signal, and the human data simply does not exist.

Because of this profile, Adipotide is best understood as a subject of scientific study and discussion rather than as a usable product. It is not a treatment, it is not approved by regulators, and the kidney toxicity reported in primate research has led it to be widely regarded as unsafe for human use. This page is an educational reference summarizing what Adipotide is, why researchers examined it, and the honest state of the evidence. It does not provide dosing, protocols, sourcing, or medical advice. Anyone encountering Adipotide in a research or commercial context should recognize that it carries serious, documented safety concerns and remains far from any validated therapeutic use.

Evidence grade: D

None established; primate studies showed renal toxicity. Weight loss with nephrotoxicity reported.

Human evidence

None established; primate studies showed renal toxicity.

Animal and preclinical evidence

Weight loss with nephrotoxicity reported.

Proposed mechanisms

Targets vasculature of white adipose tissue

Safety concerns and known side effects

Documented kidney toxicity in primate studies. Considered unsafe for human use.

Renal toxicity (in studies)
Dehydration

Regulatory status

Not an approved medicine. Experimental; significant safety concerns.

Adipotide research timeline

Mid-2000s
Researchers at a US cancer center describe a peptidomimetic (later called FTPP/Adipotide) that homes to a prohibitin marker on the blood vessels feeding white fat and carries a proapoptotic sequence to kill that vasculature.
Late 2000s
Early rodent work reports that cutting off the fat tissue's blood supply causes measurable weight and fat loss in obese animals, establishing the anti-angiogenic proof of concept.
Early 2010s
A widely publicized non-human primate study shows spontaneous weight loss in obese monkeys but also documents kidney (renal) toxicity, flagging a serious safety signal.
Early-to-mid 2010s
The renal-toxicity finding and lack of an established safety margin stall progress; no large, well-documented human efficacy trials enter mainstream medical literature.
2010s-2020s
Despite never being approved, the compound circulates on the research-chemical/grey market and in fitness forums as an experimental fat-loss agent, prompting repeated safety warnings from commentators.
Present
Adipotide remains an unapproved, experimental compound with no accepted human therapeutic use, defined largely by its documented nephrotoxicity rather than any validated benefit.

Frequently asked questions about Adipotide

What is Adipotide?: Adipotide (also called FTPP or Prohibitin-TP01) is an experimental peptidomimetic designed to target the blood supply of white fat tissue. It is a research compound, not an approved medicine.
What does research suggest about Adipotide?: In animal studies, including obese non-human primates, Adipotide produced weight and fat-mass loss. However, the same studies also reported kidney toxicity, and there is no established human clinical evidence of safety or benefit.
Is Adipotide approved or safe for human use?: No. Adipotide is not an approved medicine in any jurisdiction and has never been shown to be safe in humans. It is considered experimental with significant safety concerns and is not intended for human use.
What are the known side effects of Adipotide?: The most significant documented concern is renal (kidney) toxicity observed in primate studies. Dehydration has also been noted. Its full safety profile in humans is unknown because human data does not exist.
How does Adipotide work?: Adipotide was engineered to target the vasculature of white adipose tissue, aiming to reduce the blood supply that sustains fat stores. This mechanism differs from appetite- or metabolism-based approaches and is described only from preclinical research.
What is the legal and regulatory status of Adipotide?: Adipotide is not approved as a medicine and holds an experimental research status. Commercial availability is restricted, and it is not a validated or legal therapeutic product for human use.
How is Adipotide's mechanism different from GLP-1 fat-loss drugs like semaglutide?: They work in completely different ways. GLP-1 receptor agonists act on appetite and metabolic signaling to reduce food intake and body weight, and are approved medicines with large trial programs. Adipotide instead tries to destroy the blood vessels that supply fat tissue, an anti-angiogenic/proapoptotic approach that was never approved and is associated with kidney toxicity in studies. Comparing the two is educational only, not a suggestion to use either without medical oversight.
Why does Adipotide still get talked about if it was never approved?: Much of the attention traces back to a single dramatic primate study in which obese monkeys lost weight. That striking imagery spread widely and gave the compound a reputation as a 'targeted' fat-loss agent. What often gets left out of that retelling is the accompanying kidney toxicity and the absence of successful human trials, which is why its popularity outpaces its actual evidence base.
Is Adipotide a 'natural' hormone or peptide the body makes?: No. This is a common misconception. It is a synthetic, engineered peptidomimetic built from a fat-vasculature homing sequence linked to a cell-killing sequence. It is not a naturally occurring hormone, and its design goal was to selectively damage adipose blood supply rather than to mimic a normal signaling molecule.
Where can I buy Adipotide and compare vendors?: Use the vendor comparison on this page. It shows only checked, product-specific links and identifies vendor claims, independent documentation and affiliate relationships separately. Availability and legal status can vary by country.

Common discussion areas

Fat lossSafety concerns

Sources

A Peptidomimetic Targeting White Fat Causes Weight Loss and Improved Insulin Resistance in Obese Monkeys — Science Translational Medicine · PubMed

Editorial review and transparency

Written by: peptides.cx Editorial Team
Scientific reviewer: No named medical reviewer is currently assigned
Last editorial review: June 1, 2026
Last vendor check: July 18, 2026
Review method: Source review, claim verification, vendor-data separation and regulatory-context review.
Commercial disclosure and conflicts: Vendor relationships do not determine evidence or safety ratings. No named reviewer conflict is recorded because no named reviewer is assigned.

Editorial policy →Evidence grade →Vendor methodology →

Related on peptides.cx

Library →Vendor quality checklist →Safety →Affiliate code: PEPTIDES10